



theconversation.com8d ago
In a retrospective analysis, Jin Ding and colleagues explore the discrepancy in regulatory authorization of orphan drugs by U.S. and European regulatory agencies.
Learn about FDA’s innovative approaches to respond to COVID-19 as quickly and safely as possible.



Shared by @TheAtlantic ↗

theconversation.com14d ago




Shared by @JAMA_current ↗
Shared by @Medscape ↗


